Orphanet Journal of Rare Diseases | Iran Publishes First Guidelines for Diagnosis and Management of Mitochondrial Disorders

Recommend:

This article presents the first clinical management guidelines for mitochondrial disorders in Iran based on evidence-based medicine and expert consensus, with a particular focus on feasibility in resource-limited settings. It covers comprehensive content from clinical manifestations, biomarkers, imaging features, genetic diagnosis to treatment strategies and anesthetic management.

 

Literature Overview
This article, titled 'Comprehensive Iranian guidelines for the diagnosis and management of mitochondrial disorders: an evidence- and consensus-based approach', published in the Orphanet Journal of Rare Diseases, reviews and summarizes clinical manifestations, diagnostic procedures, and management strategies for mitochondrial disorders. The research team developed a standardized scoring system and treatment protocol suitable for resource-limited environments through systematic literature review and multidisciplinary expert discussion. The article highlights real-world challenges in managing mitochondrial disorders in developing countries, such as high costs of genetic testing, lack of specific nutritional supplements, and insufficient expert support. The guidelines aim to improve diagnostic accuracy, optimize treatment strategies, and enhance the quality of life for patients in Iran and other resource-constrained areas.

Background Knowledge
Mitochondrial disorders are a group of rare inherited metabolic diseases caused by mitochondrial dysfunction, primarily affecting high-energy-demand organs such as the brain, heart, muscles, and liver. These disorders are highly heterogeneous and can be caused by mutations in mitochondrial DNA (mtDNA) or nuclear DNA (nDNA), with clinical presentations ranging from single organ dysfunction to multi-system involvement. Currently, there is no cure for mitochondrial disorders, and management mainly relies on supportive care and symptom management. Diagnostically, elevated blood lactate and alanine levels, along with characteristic brain MRI findings, are common clues but lack specificity, requiring confirmation through genetic and functional analysis. However, whole-genome or whole-exome sequencing remains challenging in resource-limited areas due to high costs and limited equipment. This study was conducted against this backdrop, developing adapted guidelines tailored to Iran's healthcare system and resource availability, integrating MDC scoring system, imaging, biochemical markers, and genetic testing to provide clinicians with practical tools. Additionally, the guidelines emphasize special considerations in anesthetic management, including drug selection and preoperative preparation, to reduce perioperative risks for mitochondrial disease patients.

 

Evaluate the pathogenicity of gene variants and provide a reference for functional analysis.

Learn More

 

Research Methods and Experiments
The research team systematically searched major biomedical databases including PubMed, Scopus, Web of Science, Cochrane, and Embase from 2000 to 2023 to identify relevant literature on clinical manifestations, diagnosis, and management of mitochondrial disorders. Subsequently, certified experts in genetics, metabolism, radiology, and pediatrics from Iran were invited to form a multidisciplinary panel to review the literature and develop locally adapted clinical recommendations. Each expert was responsible for drafting a specific section, and consensus was reached through multiple rounds of revision and discussion. The study focused particularly on resource-limited settings, emphasizing practical approaches based on available equipment and diagnostic tools, such as routine MRI, biochemical screening, and the MDC scoring system.

Key Findings and Perspectives

• The clinical manifestations of mitochondrial disorders are diverse, including common symptoms such as developmental delay, epilepsy, muscle weakness, cardiomyopathy, and endocrine abnormalities.
• Biochemical markers include elevated blood lactate and alanine, abnormal Krebs cycle intermediates, and organic acids.
• MRI is an important tool for assessing central nervous system involvement, with typical findings including abnormal signals in the basal ganglia, brainstem, and cerebellum.
• Whole exome sequencing (WES) and mtDNA sequencing are the main genetic diagnostic tools, but in resource-limited settings, the MDC scoring system can be prioritized to assist diagnosis.
• Supportive therapies include vitamin B50 complex, coenzyme Q10, L-carnitine, and antioxidants.
• During acute episodes, fasting should be avoided, and glucose-containing fluids should be used to support energy metabolism. Certain toxic drugs such as valproic acid should also be avoided.
• In anesthetic management, intravenous agents like propofol should be used cautiously, with preference given to local anesthesia, while maintaining normal body temperature and blood glucose levels.
• Future research should focus on more specific therapeutic strategies and clinical applications of gene therapy.

Significance and Future Directions
This study represents the first clinical guideline for mitochondrial disorders in Iran, providing a feasible diagnostic and management framework for resource-limited settings. By integrating the MDC scoring system, the clinical recognition process for mitochondrial disorders is simplified. Future work should further validate the diagnostic performance of this scoring system in the Iranian population and explore genotype-phenotype correlations for personalized treatment strategies to enhance therapeutic precision.

 

Input a gene and explore its associated signaling pathways and known upstream/downstream molecules.

Learn More

 

Conclusion
Mitochondrial disorders are complex inherited metabolic conditions primarily affecting tissues with high energy demands, such as the brain, heart, liver, and muscles. These disorders exhibit high clinical heterogeneity, and diagnosis requires integration of clinical manifestations, biochemical markers, imaging findings, and genetic testing. This article presents the first mitochondrial disorder management guidelines tailored to Iran's healthcare resources, emphasizing the use of the MDC scoring system in resource-limited settings to assist clinical judgment. Supportive treatments such as vitamin B50 complex, coenzyme Q10, and antioxidants are recommended, with special attention to drug selection and perioperative considerations in anesthetic management. The guidelines provide a structured approach for clinicians, particularly in developing countries. In the future, more effective etiological treatments may be achieved through advances in gene therapy and mitochondrial replacement techniques, but for now, symptom management and metabolic support remain the mainstay. Through systematic literature review and expert consensus, this article provides practical clinical references for Iran and other regions with limited healthcare resources.

 

Setila Dalili, Noushin Rostampour, Seyedeh Tahereh Mousavi, Ali Talea, and Hossein Moravvej. Comprehensive Iranian guidelines for the diagnosis and management of mitochondrial disorders: an evidence- and consensus-based approach. Orphanet Journal of Rare Diseases.